SCHEMBL973777

SCHEMBL973777

Cc1nc2cc(NC(=O)c3cc4cc(C(F)(F)F)cnc4n3Cc3cccc(F)c3)ccn2c1C

nearest known ligand 0.39

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.38
TP53 P04637 1/20 0.38
MAPT P10636 1/20 0.38
MAOB P27338 1/20 0.37
NR3C1 P04150 3/20 0.36
KIT P10721 1/20 0.36
DDR2 Q16832 1/20 0.36
PPARG P37231 4/20 0.36
GRIN1 Q05586 1/20 0.36
GRIN2B Q13224 1/20 0.36
CSF1R P07333 1/20 0.36
THRB P10828 1/20 0.36
UBE2M P61081 1/20 0.35
DCUN1D1 Q96GG9 1/20 0.35
ECE1 P42892 1/20 0.35
ACKR3 P25106 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL974569 0.88 ECE1 (0.44) PPARGECE1
SCHEMBL975216 0.83 SCD (0.37) MAPTMAOBKITDDR2PPARG
SCHEMBL974351 0.83 MCHR1 (0.40) MAPTMAOBPPARGGRIN1GRIN2B
SCHEMBL975576 0.83 ECE1 (0.47) MAOBECE1
SCHEMBL974077 0.82 KDM4E (0.41) LMNAMAPTMAOBACKR3
SCHEMBL2814196 0.81 MAOB (0.49) TP53MAPTMAOBPPARGGRIN1
SCHEMBL1099566 0.81 KCNQ3 (0.48) MAPTMAOBNR3C1PPARGGRIN1
SCHEMBL926852 0.81 MAOB (0.41) MAPTMAOBPPARGGRIN1GRIN2B
SCHEMBL973793 0.81 MAOB (0.40) LMNAMAPTMAOBPPARGGRIN1
SCHEMBL1099650 0.81 PPARG (0.40) MAPTMAOBPPARGGRIN1GRIN2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2235016-B1 AZABICYCLIC CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2013-09-18 EP claimed
US-8394820-B2 N-azabicyclic carboxamide derivatives, preparation thereof and therapeutic use thereof SANOFI (FR) 2013-03-12 US claimed
CN-101977910-A Azabicyclic carboxamide derivatives, preparation and therapeutic use thereof SANOFI AVENTIS 2011-02-16 CN claimed
US-20110009444-A1 N-AZABICYCLIC CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-01-13 US claimed
EP-2235016-B1 AZABICYCLIC CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2013-09-18 EP disclosed
CN-101977910-B Azabicyclic carboxamide derivatives, preparation and therapeutic use thereof SANOFI AVENTIS 2013-08-07 CN disclosed
US-8394820-B2 N-azabicyclic carboxamide derivatives, preparation thereof and therapeutic use thereof SANOFI (FR) 2013-03-12 US disclosed
CN-101977910-A Azabicyclic carboxamide derivatives, preparation and therapeutic use thereof SANOFI AVENTIS 2011-02-16 CN disclosed
US-20110009444-A1 N-AZABICYCLIC CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110009444-A1 N-AZABICYCLIC CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF XDH, NQO2, SLC28A2 LMNA 649/4885TP53 1859/4885MAPT 3452/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.